Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 221Carcinoma, Non-Small-Cell Lung 218Prostatic Neoplasms 150Multiple Myeloma 140Neoplasms 129Colorectal Neoplasms 117Leukemia, Myeloid, Acute 106Lung Neoplasms 102Neoplasm Metastasis 95Squamous Cell Carcinoma of Head and Neck 91Carcinoma, Hepatocellular 84Lymphoma 78Melanoma 77Triple Negative Breast Neoplasms 71Pancreatic Neoplasms 71Ovarian Neoplasms 66Sarcoma 64Lymphoma, Large B-Cell, Diffuse 61Carcinoma, Renal Cell 59Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Head and Neck Neoplasms 57Recurrence 56Brain Neoplasms 56Lymphoma, Non-Hodgkin 53Hematologic Neoplasms 52Stomach Neoplasms 51Leukemia, Lymphocytic, Chronic, B-Cell 51Endometrial Neoplasms 50Small Cell Lung Carcinoma 48Rectal Neoplasms 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Giant Cell Tumor of Tendon Sheath × 90 days × Clear all
NCT07499362 2026-05-28

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Recruiting
20 enrolled

Giant Cell Tumor of Tendon Sheath

Data powered by HemOnc (CC BY 4.0) Colophon âš¡